Drug Type CAR-T |
Synonyms 19CP02 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization CellPoint BVStartup |
Active Organization- |
Inactive Organization CellPoint BVStartup |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 2 | BE | CellPoint BVStartup | 27 Oct 2021 |
Non-Hodgkin Lymphoma | Phase 2 | NL | CellPoint BVStartup | 27 Oct 2021 |